GlassScriptPhysician profile
Robert G Shupe
NPI 1811272297
$6,774.83
in general payments reported to CMS, 2019-2025
30 companies · $2,299 in 2025
The $2,299 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $69.40 · 2022: $291 · 2023: $1,830 · 2024: $2,286 · 2025: $2,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,414.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,241.20 | 2023-2025 | |
| Axsome Therapeutics, INC. | $822.66 | 2023-2025 | Auvelity, Sunosi |
| Corium, LLC | $822.02 | 2022-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $519.22 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $472.70 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $458.97 | 2023-2025 | Rexulti |
| Tris Pharma INC | $312.39 | 2023-2025 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $270.12 | 2022-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $227.73 | 2024-2025 | Aristada, Lybalvi |
| Ironshore Pharmaceuticals INC. | $195.22 | 2023-2024 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $171.37 | 2022-2025 | Spravato |
| Merck Sharp & Dohme LLC | $160.58 | 2022-2023 | Belsomra |
| Supernus Pharmaceuticals, INC. | $147.26 | 2024-2025 | Qelbree |
| Bausch Health US, LLC | $124.28 | 2024-2025 | Aplenzin |
| Teva Pharmaceuticals USA, INC. | $112.47 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $96.45 | 2023-2025 | Relexxii |
| Neos Therapeutics, LP | $92.33 | 2022-2024 | Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $72.40 | 2023-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $65.64 | 2025 | Cobenfy |
| Almatica Pharma LLC | $63.46 | 2024 | Loreev Xr |
| Stryker Corporation | $52.07 | 2021-2022 | |
| Djo, LLC | $48.22 | 2022 | |
| Idorsia Pharmaceuticals US INC | $46.63 | 2022-2024 | Quviviq |
| Depuy Synthes Sales INC. | $44.59 | 2021-2022 | |
| Bioventus LLC | $38.35 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $32.78 | 2025 | Jornay Pm |
| Biogen, INC. | $23.32 | 2023 | |
| Livanova USA, INC. | $16.21 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Orthofix Medical, INC. | $16.10 | 2021 | |
| Dynasplint Systems INC. | $8.09 | 2023 | Dynasplint |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Shupe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.